Targeting Mitochondria in Cardiovascular Diseases

Author(s): Filomena S.G. Silva, Rui F. Simoes, Renata Couto, Paulo J. Oliveira.

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 37 , 2016

Become EABM
Become Reviewer

Abstract:

Background: Cardiovascular diseases (CVDs) are one of the main factors responsible for human morbidity and mortality. Since mitochondria play a critical role in the regulation of cardiac tissue homeostasis, this organelle is a critical target for the protective effects of several pharmaceuticals. Although specific mitochondria-targeted antioxidants and some pharmacological agents are described as potential cardioprotective agents, there are still a few effective mitochondrial therapies for the treatment of CVDs. Agents which have potential cardioprotective effects by directly targeting mitochondria in vitro and in vivo are still in pre-clinical or clinical trials, hence their widespread use in the clinic is still far. Also, some of these agents have a decreased bioavailability or show some intrinsic toxicity, which also limits their working mitochondrial concentrations.

Methods: By initially using PubMed specific queries for literature search, we review here cardiac mitochondrial effects of specific targeted and non-targeted antioxidants and pharmacological agents, including MitoE, MitoQ, MitoSNO, Mito-TEMPOL, SkQ1, SkQR1, carvedilol, trimetazidine, ranolazine, diazoxide and propofol.

Results: The present review emphasizes new mitochondrial-targeting strategies which have emerged to address difficulties arising from current approaches. We also describe the strengths and weaknesses of these cardioprotective approaches.

Conclusion: Although effective therapies to target mitochondria in the context of CVDs are not under widespread clinical use, the new strategies proposed constitute a real promise for the development of therapies which may effectively prevent CVDs in the near future.

Keywords: Ischaemia-reperfusion injury, heart mitochondria, mitochondria-targeted antioxidants, cardioprotective agents, oxidative stress, calcium overload, mitochondrial permeability transition pore, mitochondrial biogenesis, drugs.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 22
ISSUE: 37
Year: 2016
Page: [5698 - 5717]
Pages: 20
DOI: 10.2174/1381612822666160822150243
Price: $58

Article Metrics

PDF: 40
HTML: 2
EPUB: 1
PRC: 1